Sanofi Debt to Equity Ratio 2006-2018 | SNY

Current and historical debt to equity ratio values for Sanofi (SNY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Sanofi debt/equity for the three months ending March 31, 2018 was 0.40.
Sanofi Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-03-31 $0.00B $0.00B 0.00
2017-12-31 $16.19B $65.85B 0.25
2017-09-30 $0.00B $0.00B 0.00
2017-06-30 $16.71B $63.58B 0.26
2017-03-31 $0.00B $0.00B 0.00
2016-12-31 $18.61B $63.88B 0.29
2016-09-30 $0.00B $0.00B 0.00
2016-06-30 $16.78B $61.39B 0.27
2016-03-31 $0.00B $0.00B 0.00
2015-09-30 $0.00B $0.00B 0.00
2015-06-30 $11.91B $62.80B 0.19
2014-06-30 $13.87B $71.01B 0.20
2013-06-30 $13.96B $73.39B 0.19
2012-06-30 $13.20B $72.42B 0.18
2012-03-31 $0.00B $0.00B 0.00
2011-12-31 $17.41B $78.54B 0.22
2011-09-30 $0.00B $0.00B 0.00
2011-06-30 $19.12B $75.69B 0.25
2011-03-31 $0.00B $0.00B 0.00
2010-12-31 $8.89B $70.76B 0.13
2010-09-30 $0.00B $0.00B 0.00
2010-06-30 $9.01B $67.09B 0.13
2010-03-31 $0.00B $0.00B 0.00
2009-12-31 $8.31B $67.56B 0.12
2009-09-30 $0.00B $0.00B 0.00
2009-06-30 $9.51B $61.00B 0.16
2009-03-31 $0.00B $0.00B 0.00
2008-12-31 $6.14B $66.31B 0.09
2008-09-30 $0.00B $0.00B 0.00
2008-06-30 $6.69B $64.83B 0.10
2008-03-31 $0.00B $0.00B 0.00
2007-12-31 $5.12B $61.30B 0.08
2007-09-30 $0.00B $0.00B 0.00
2007-06-30 $5.64B $62.17B 0.09
2007-03-31 $0.00B $0.00B 0.00
2006-12-31 $5.65B $57.56B 0.10
2006-09-30 $0.00B $0.00B 0.00
2006-06-30 $4.67B $56.70B 0.08
2006-03-31 $0.00B $0.00B 0.00
2005-12-31 $5.92B $58.32B 0.10
2005-09-30 $0.00B $0.00B 0.00
2005-06-30 $8.98B $56.24B 0.16
2005-03-31 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $112.713B $39.599B
Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $396.345B 18.58
Pfizer (PFE) United States $262.998B 14.83
Merck (MRK) United States $205.854B 17.84
Novartis AG (NVS) Switzerland $204.655B 17.49
AbbVie (ABBV) United States $134.597B 11.95
Eli Lilly (LLY) United States $122.680B 21.57
Novo Nordisk (NVO) Denmark $111.107B 18.04
AstraZeneca (AZN) United Kingdom $103.342B 12.83
GlaxoSmithKline (GSK) United Kingdom $101.256B 13.61
Bristol-Myers Squibb (BMY) United States $87.290B 14.38